Cargando…

A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France

OBJECTIVE: To describe the characteristics, management and outcomes of hospitalised patients with Clostridioides difficile infection (CDI) treated with and without fidaxomicin. METHODS: This prospective, multicentre, observational study (DAFNE) enrolled hospitalised patients with CDI, including 294...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guery, Benoit, Berger, Pierre, Gauzit, Remy, Gourdon, Magali, Barbut, Frédéric, DAFNE study group:, Bémer, Pascale, Bessède, Emilie, Camou, Fabrice, Cattoir, Vincent, Couzigou, Carine, Descamps, Dominique, Dinh, Aurélien, Laurans, Caroline, Lavigne, Jean-Philippe, Lechiche, Catherine, Leflon-Guibout, Véronique, Le Monnier, Alban, Levast, Marion, Mootien, Joy Yoganaden, N’Guyen, Yohan, Piroth, Lionel, Prazuck, Thierry, Rogeaux, Olivier, Roux, Anne-Laure, Vachée, Anne, Vernet Garnier, Véronique, Wallet, Frédéric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Prospective Clinical Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236878/ https://www.ncbi.nlm.nih.gov/pubmed/34162264 http://dx.doi.org/10.1177/03000605211021278

Ejemplares similares

Efflux Pump, the Masked Side of ß-Lactam Resistance in Klebsiella pneumoniae Clinical Isolates
por: Pages, Jean-Marie, et al.
Publicado: (2009)

Antimicrobial Activities of Fidaxomicin
por: Goldstein, Ellie J. C., et al.
Publicado: (2012)

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses
por: Cornely, Oliver A., et al.
Publicado: (2019)

The ST131 Escherichia coli H22 subclone from human intestinal microbiota: Comparison of genomic and phenotypic traits with those of the globally successful H30 subclone
por: Nicolas-Chanoine, Marie-Hélène, et al.
Publicado: (2017)

Patient's Origin and Lifestyle Associated with CTX-M-Producing Escherichia coli: A Case-Control-Control Study
por: Nicolas-Chanoine, Marie-Hélène, et al.
Publicado: (2012)

An Economic Analysis: Is Fidaxomicin Worth the Cost?
por: Shah, Hemal, et al.
Publicado: (2014)

675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
por: Cook, Ellen, et al.
Publicado: (2023)

In vitro activity of fidaxomicin and combinations of fidaxomicin with other antibiotics against Clostridium perfringens strains isolated from dogs and cats
por: Álvarez-Pérez, Sergio, et al.
Publicado: (2023)

Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study
por: Wilcox, Mark H, et al.
Publicado: (2019)

Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis
por: Artsimovitch, Irina, et al.
Publicado: (2012)

Fidaxomicin Inhibits Spore Production in Clostridium difficile
por: Babakhani, Farah, et al.
Publicado: (2012)

Fidaxomicin - the new drug for Clostridium difficile infection
por: Vaishnavi, Chetana
Publicado: (2015)

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
por: Oliver, Meredith B, et al.
Publicado: (2022)

Hypervirulent Klebsiella pneumoniae in Cryptogenic Liver Abscesses, Paris, France
por: Rossi, Benjamin, et al.
Publicado: (2018)

Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
por: Chaparro-Rojas, Fredy, et al.
Publicado: (2013)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

Novel fidaxomicin antibiotics through site-selective catalysis
por: Dailler, David, et al.
Publicado: (2021)

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
por: Zhanel, George G, et al.
Publicado: (2015)

Fidaxomicin Use and Clinical Outcomes for Clostridium difficile–Associated Diarrhea
por: Eiland, Edward H., et al.
Publicado: (2015)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Semisynthetic Analogs of the Antibiotic Fidaxomicin—Design, Synthesis, and Biological Evaluation
por: Dorst, Andrea, et al.
Publicado: (2020)

Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection
por: Heleno, Caio T, et al.
Publicado: (2021)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
por: Nathwani, Dilip, et al.
Publicado: (2014)

Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects
por: Oshima, Hiroyuki, et al.
Publicado: (2015)

A multi-center study of fidaxomicin use for Clostridium difficile infection
por: Shah, Dhara N., et al.
Publicado: (2016)

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
por: Lee, Christine, et al.
Publicado: (2016)

Molecular dissection of RbpA-mediated regulation of fidaxomicin sensitivity in mycobacteria
por: Prusa, Jerome, et al.
Publicado: (2022)

Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?
por: Patel, Devangi, et al.
Publicado: (2023)

Case Report of an Injectional Anthrax in France, 2012
por: Thouret, Jean-Marc, et al.
Publicado: (2020)

Fidaxomicin for Clostridium difficile-Associated Diarrhoea: Epidemiological Method for Estimation of Warranted Price
por: Sclar, David Alexander, et al.
Publicado: (2012)

467 Analysis of Clinical and Economical Outcomes of Fidaxomicin Use for Clostridium difficile infections
por: Flaherty, Sarah, et al.
Publicado: (2014)

Fidaxomicin Use for Clostridium Difficile Infection Probably Decreases the Effect of Coumadin® in Elderly
por: Dhruv, Samyak, et al.
Publicado: (2020)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

1982. Multiplex PCR-Based Analysis of Enteric Pathogens in Faecal Samples from Patients with Clostridium difficile Infection in the Randomized, Controlled EXTEND Study Comparing the Efficacy of Extended-Pulsed Fidaxomicin With Vancomycin Therapy
por: Wilcox, Mark, et al.
Publicado: (2018)

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
por: Figueroa, Iris, et al.
Publicado: (2012)

Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l0sq2g8o7ne3kmsab4hqqpf1ob